Orros Biotherapeutics

Orros Biotherapeutics is a private early-stage biotechnology company focused on the discovery of antibody therapeutics. Publicly available information about the company is sparse, but external disclosures and executive biographies indicate that it was co-founded in 2017 and was pursuing antibody-based drug discovery. The company appears to have operated primarily as a small private discovery-stage biotech rather than a clinical-stage developer with a broadly disclosed pipeline. No clear evidence of clinical programs, marketed products, or major commercial services was identified in public sources. Based on the limited available information, Orros Biotherapeutics is best characterized as a preclinical antibody therapeutics startup.